LIWANLI Innovation Co., Ltd. (3054.TW)
TWD 24.35
(2.31%)
TWD 24.35
(2.31%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -244.02 Million TWD | 16.95% |
| 2022 | -293.81 Million TWD | -37.58% |
| 2021 | -213.56 Million TWD | 31.22% |
| 2020 | -310.49 Million TWD | 10.19% |
| 2019 | -345.72 Million TWD | -15.48% |
| 2018 | -299.36 Million TWD | 59.45% |
| 2017 | -738.18 Million TWD | -146.08% |
| 2016 | -299.97 Million TWD | -44.27% |
| 2015 | -207.92 Million TWD | -17993.89% |
| 2014 | 1.16 Million TWD | 100.22% |
| 2013 | -531.38 Million TWD | -783.86% |
| 2012 | 77.7 Million TWD | 180.05% |
| 2011 | -97.06 Million TWD | 80.33% |
| 2010 | -493.5 Million TWD | -68.27% |
| 2009 | -293.28 Million TWD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -239.81 Million TWD | -1.05% |
| 2024 Q3 | -239.76 Million TWD | 0.02% |
| 2024 Q1 | -237.32 Million TWD | 2.75% |
| 2023 Q2 | -253.95 Million TWD | 12.1% |
| 2023 FY | -244.02 Million TWD | 16.95% |
| 2023 Q1 | -288.92 Million TWD | 1.67% |
| 2023 Q4 | -244.02 Million TWD | -1.78% |
| 2023 Q3 | -239.75 Million TWD | 5.59% |
| 2022 FY | -293.81 Million TWD | -37.58% |
| 2022 Q4 | -293.81 Million TWD | -16.63% |
| 2022 Q3 | -251.93 Million TWD | -28.43% |
| 2022 Q2 | -196.16 Million TWD | -10.44% |
| 2022 Q1 | -177.61 Million TWD | 16.83% |
| 2021 Q1 | -367.42 Million TWD | -18.33% |
| 2021 Q4 | -213.56 Million TWD | 21.74% |
| 2021 Q3 | -272.88 Million TWD | 39.3% |
| 2021 FY | -213.56 Million TWD | 31.22% |
| 2021 Q2 | -449.56 Million TWD | -22.35% |
| 2020 FY | -310.49 Million TWD | 10.19% |
| 2020 Q4 | -310.49 Million TWD | 4.31% |
| 2020 Q3 | -324.48 Million TWD | -7.17% |
| 2020 Q1 | -245.52 Million TWD | 28.98% |
| 2020 Q2 | -302.76 Million TWD | -23.32% |
| 2019 FY | -345.72 Million TWD | -15.48% |
| 2019 Q4 | -345.72 Million TWD | -1.66% |
| 2019 Q2 | -337.93 Million TWD | 8.44% |
| 2019 Q1 | -369.09 Million TWD | -23.29% |
| 2019 Q3 | -340.08 Million TWD | -0.64% |
| 2018 Q3 | -597.48 Million TWD | 14.82% |
| 2018 Q1 | -649.14 Million TWD | 12.06% |
| 2018 FY | -299.36 Million TWD | 59.45% |
| 2018 Q4 | -299.36 Million TWD | 49.9% |
| 2018 Q2 | -701.41 Million TWD | -8.05% |
| 2017 Q3 | -405.81 Million TWD | -11.76% |
| 2017 Q2 | -363.11 Million TWD | -16.32% |
| 2017 Q1 | -312.17 Million TWD | -4.07% |
| 2017 FY | -738.18 Million TWD | -146.08% |
| 2017 Q4 | -738.18 Million TWD | -81.9% |
| 2016 Q1 | -164.36 Million TWD | 20.95% |
| 2016 FY | -299.97 Million TWD | -44.27% |
| 2016 Q4 | -299.97 Million TWD | -6.58% |
| 2016 Q3 | -281.45 Million TWD | -420.15% |
| 2016 Q2 | 87.91 Million TWD | 153.49% |
| 2015 Q3 | -273.41 Million TWD | 12.25% |
| 2015 Q4 | -207.92 Million TWD | 23.95% |
| 2015 FY | -207.92 Million TWD | -17993.89% |
| 2015 Q1 | -307.98 Million TWD | -26604.82% |
| 2015 Q2 | -311.59 Million TWD | -1.17% |
| 2014 Q1 | -215.12 Million TWD | 59.52% |
| 2014 Q4 | 1.16 Million TWD | -87.56% |
| 2014 FY | 1.16 Million TWD | 100.22% |
| 2014 Q3 | 9.33 Million TWD | 102.29% |
| 2014 Q2 | -407.55 Million TWD | -89.45% |
| 2013 Q2 | -135.82 Million TWD | -173.03% |
| 2013 Q4 | -531.38 Million TWD | -167.33% |
| 2013 FY | -531.38 Million TWD | -783.86% |
| 2013 Q1 | 185.98 Million TWD | 139.35% |
| 2013 Q3 | -198.77 Million TWD | -46.34% |
| 2012 Q4 | 77.7 Million TWD | 3.52% |
| 2012 Q3 | 75.06 Million TWD | 164.95% |
| 2012 FY | 77.7 Million TWD | 180.05% |
| 2012 Q2 | 28.33 Million TWD | 172.32% |
| 2012 Q1 | -39.17 Million TWD | 59.64% |
| 2011 Q3 | 135.71 Million TWD | 150.1% |
| 2011 Q4 | -97.06 Million TWD | -171.52% |
| 2011 Q2 | -270.86 Million TWD | 41.11% |
| 2011 Q1 | -459.96 Million TWD | 6.8% |
| 2011 FY | -97.06 Million TWD | 80.33% |
| 2010 FY | -493.5 Million TWD | -68.27% |
| 2010 Q4 | -493.5 Million TWD | 0.0% |
| 2009 FY | -293.28 Million TWD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Grape King Bio Ltd | -4.62 Billion TWD | 94.725% |
| Standard Chem & Pharm CO., LTD. | -954.74 Million TWD | 74.441% |
| Maywufa Company Ltd. | 264.18 Million TWD | 192.368% |
| ScinoPharm Taiwan, Ltd. | -3.32 Billion TWD | 92.651% |
| Lotus Pharmaceutical Co., Ltd. | 9.81 Billion TWD | 102.487% |
| YungShin Global Holding Corporation | -247.5 Million TWD | 1.405% |
| PhytoHealth Corporation | -34.64 Million TWD | -604.434% |
| SCI Pharmtech, Inc. | 100.41 Million TWD | 343.01% |
| Formosa Laboratories, Inc. | 2.53 Billion TWD | 109.613% |
| PharmaEssentia Corporation | -18.46 Billion TWD | 98.679% |
| Bora Pharmaceuticals Co., LTD. | 1.95 Billion TWD | 112.472% |